Aug 2026· Journal of Genetic and Environment Conservation· 0 citations· 30 references
TL;DR
The current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease is reviewed and modern approaches for diagnosis and treatment are discussed.
Abstract
Alzheimer's disease (AD) is the primary cause of dementia globally and the most prevalent neurodegenerative disease. Progressive memory loss, cognitive impairment, behavioral abnormalities, and loss of functional independence are its hallmarks. The development of Alzheimer’s disease is strongly associated with both genetic predisposition and physiological dysfunctions within the central nervous system. Modern scientific advances have revealed that multiple genes, including APOE, APP, PSEN1, and PSEN2, contribute to disease susceptibility and progression. Furthermore, the disease's key clinical features include physiological anomalies such amyloid-beta buildup, tau hyper-phosphorylation, neuro-inflammation, oxidative stress, mitochondrial dysfunction, and synaptic degeneration. Additionally, recent research highlights the importance of cellular senescence, non-coding RNAs, and epigenetics in the pathophysiology of AD. Understanding the relationship between genetics and physiology provides new opportunities for early diagnosis and targeted therapeutic interventions. This article reviews the current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease and discusses modern approaches for diagnosis and treatment.
A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.
The importance of bridging mechanistic research with real-world clinical practice to generate impactful diagnostic, therapeutic, and policy outcomes is highlighted.
Sayed Hussain Amiri, Arman Qudosy, Sayed Mohammad Jawad Wasiq et al.· Afghanistan Journal of Basic...· 0 citations
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
Progress in multi-omics technologies, disease models using induced pluripotent stem cells (iPSC), gene editing with CRISPR-Cas9, and artificial intelligence (AI) analysis are likely to speed up the implementation of precision medicine for early diagnosis, risk prediction, and treatment of Alzheimer's disease.
Sumithira George, Sharan Kumar, Sivakumar Subramaniyan et al.· Middle East Research Journal...· 0 citations
This paper systematically reviews the progression of AD, categorizing it into three stages: the subjective cognitive decline, mild cognitive impairment and AD dementia and describes its progression from early latent symptoms to severe functional impairment in middle and late stages.
Yishan Li· Theoretical and Natural Scie...· 0 citations
Evidence supports a shift from a linear amyloid model to a multidimensional framework and offers promise for early detection, risk stratification, and personalized multi-target therapies in AD.
C. D. Souza, Shiva Murthy Nanjundappa, N. Murali· International Journal of Bas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.